Surmodics acquired by GTCR-backed BCE Parent for $43.00/share; stock to be delisted

SURMODICS INC

Completion of merger on November 19, 2025; each share of common stock converted into $43.00 cash.
Nasdaq halt on Nov 18, delisting and deregistration of SRDX requested; Form 15 to be filed.
Credit, Security and Guaranty Agreement with MidCap and related swap with Wells Fargo terminated.
All prior directors and officers replaced; Robert B. Hance appointed President/CEO, Scott D’Amour CFO.
Merger funded by GTCR equity and debt from Oak Hill Advisors, BMO, Antares, Brinley, Northwestern Mutual.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.03 item 5.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.4

SURMODICS INC issued common stock.

Security: common stock

Exact text from the filing

sting the deregistration of the Company Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act. Item 3.03 Material Modification to Rights of Security Holders. The information set forth in the Introductory Note,

View on SEC.gov

Browse all equity issuances →

Source: SEC EDGAR

accession 0001193125-25-288169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.